How Much Longer Will We Put Up With $100,000 Cancer Drugs?

Paul Workman; Giulio F Draetta; Jan H M Schellens; René Bernards

doi:10.1016/j.cell.2017.01.034

How Much Longer Will We Put Up With $100,000 Cancer Drugs?

Paul Workman
, Giulio F Draetta
, Jan H M Schellens
, René Bernards

Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK.
Department of Genomic Medicine and Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Division of Molecular Carcinogenesis and Cancer Genomics Centre Netherlands, the Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands. Electronic address: [email protected].

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The spiraling cost of new drugs mandates a fundamentally different approach to keep lifesaving therapies affordable for cancer patients. We call here for the formation of new relationships between academic drug discovery centers and commercial partners, which can accelerate the development of truly transformative drugs at sustainable prices.

Original language	English
Pages (from-to)	579-583
Number of pages	5
Journal	Cell
Volume	168
Issue number	4
DOIs	https://doi.org/10.1016/j.cell.2017.01.034
Publication status	Published - 9 Feb 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Antineoplastic Agents
Drug Approval
Drug Costs
Drug Discovery
Health Care Costs
Humans
Neoplasms
United States
Journal Article

Access to Document

10.1016/j.cell.2017.01.034

workmanFinal published version, 514 KB

Cite this

@article{2bde7219358c405ca93d2122d9806fee,

title = "How Much Longer Will We Put Up With \$100,000 Cancer Drugs?",

abstract = "The spiraling cost of new drugs mandates a fundamentally different approach to keep lifesaving therapies affordable for cancer patients. We call here for the formation of new relationships between academic drug discovery centers and commercial partners, which can accelerate the development of truly transformative drugs at sustainable prices.",

keywords = "Antineoplastic Agents, Drug Approval, Drug Costs, Drug Discovery, Health Care Costs, Humans, Neoplasms, United States, Journal Article",

author = "Paul Workman and Draetta, \{Giulio F\} and Schellens, \{Jan H M\} and Ren{\'e} Bernards",

year = "2017",

month = feb,

day = "9",

doi = "10.1016/j.cell.2017.01.034",

language = "English",

volume = "168",

pages = "579--583",

journal = "Cell",

issn = "0092-8674",